Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics is a clinical-stage biotechnology company with a strong focus on developing and commercializing fibroblast-based therapies for chronic diseases. They have a diverse pipeline of candidates, including CYWC628, CYPS317, CYMS101, and CybroCell, targeting diseases such as wound healing, multiple sclerosis, degenerative disc disease, and psoriasis. With promising preclinical data and a scalable manufacturing potential, the company's versatile fibroblast platform presents a unique opportunity for investors. However, risks include potential failures in clinical trials, securing funding, and achieving market penetration. With a strong IP portfolio and the potential for multiple indications, FibroBiologics has the potential to generate significant long-term value for investors.

Bears say

FibroBiologics is facing several challenges in their development and commercialization of fibroblast-based therapies. The initial clinical validation of their platform in DFU patients is crucial for investor engagement and success of their parallel programs. However, even if successful, the reverse stock split in 2026 may disrupt the existing shareholder base and delay potential valuation expansion. Additionally, while FibroBiologics' focus on fibroblast-based therapies is unique, it also comes with its own set of challenges and uncertainties in a relatively underexplored field of regenerative medicine. These factors, along with the potential for future competition, contribute to a negative outlook on the company's stock.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.